HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
暂无分享,去创建一个
A. Perelson | D. Ho | M. Markowitz | A. Neumann | J. Leonard
[1] N. Nathanson,et al. Experimental infection of monkeys with Langat virus. II. Turnover of circulating virus. , 1967, American journal of epidemiology.
[2] A. Dalgleish,et al. Human retroviruses , 2014, Methods in Molecular Biology.
[3] Robert Tibshirani,et al. Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .
[4] Isma'il ibn Ali al-Sadiq. AIDS , 1986, The Lancet.
[5] D. Ho,et al. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.
[6] X. Jin,et al. Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.
[7] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[8] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[9] B. Irvine,et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[10] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[11] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[12] Sebastian Bonhoeffer,et al. HIV results in the frame , 1995, Nature.
[13] D. Ho,et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.
[14] D. Ho,et al. Time to hit HIV, early and hard. , 1995, The New England journal of medicine.
[15] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] D. Ho,et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.
[17] E. Nestler,et al. Opposite Modulation of Cocaine-Seeking Behavior by D1- and D2-Like Dopamine Receptor Agonists , 1996, Science.